Novavax (NVAX) Net Income towards Common Stockholders Growth (3y) (2013 - 2026)
Powered by 
Analysis
Novavax (NVAX) Net Income towards Common Stockholders Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.26 Bn | 131.41 Bn | 2.84 Bn | 6.30% |
| 2 | Regeneron Pharmaceuticals | 85.64 Bn | 77.64 Bn | 3.93 Bn | 10.23% |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 91.31% |
| 4 | Moderna | 57.83 Bn | 52.69 Bn | 52.00 Mn | 17.25% |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 6 | BeOne Medicines | 39.94 Bn | 34.84 Bn | 1.53 Bn | 37.89% |
| 7 | Alnylam Pharmaceuticals | 35.19 Bn | 31.88 Bn | 992.69 Mn | 37.44% |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | -38.56% |
| 9 | Insmed | 27.35 Bn | 26.19 Bn | 358.27 Mn | 62.15% |
| 10 | Novavax | 1.67 Bn | 953.49 Mn | 42.45 Mn | -42.94% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -42.94% |
| Mar 31, 2026 | 68.16% |
| Dec 31, 2025 | 27.98% |
| Sep 30, 2025 | -6.27% |
| Jun 30, 2025 | 30.23% |
| Mar 31, 2025 | 36.62% |
| Dec 31, 2024 | 54.25% |
| Sep 30, 2024 | 27.81% |
| Jun 30, 2024 | 35.01% |
| Mar 31, 2024 | 12.82% |
| Dec 31, 2023 | -0.15% |
| Sep 30, 2023 | 12.81% |
| Jun 30, 2023 | 74.47% |
| Mar 31, 2023 | -124.82% |
| Dec 31, 2022 | -78.90% |
| Sep 30, 2022 | -110.61% |
| Jun 30, 2022 | -134.48% |
| Mar 31, 2022 | 88.59% |
| Dec 31, 2021 | -157.91% |
| Sep 30, 2021 | -93.43% |